menu
    • menu

    Find Dabrafenib Mesylate manufacturers, exporters & distributors on PharmaCompass

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    12

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    11

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 78,477

    MARKET PLACE

    3

    API

    1

    FDF

    15INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    18

    FDF Dossiers

    FDF Dossiers

    5

    FDA Orange Book

    FDA (Orange Book)

    5

    Europe

    Europe

    0

    Canada

    Canada

    6

    Australia

    Australia

    2

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    11DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    68

    US Patents

    28

    US Exclusivities

    2

    Health Canada Patents

    DIGITAL CONTENT

    3

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    44

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    11,709

    Finished Drug Prices

    Listed Dossiers

    107 RELATED EXCIPIENT COMPANIES

    182EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1195768-06-9, Dabrafenib (mesylate), Gsk 2118436b, Dabrafenib mesilate, Dabrafenib mesylate [usan], Unii-b6dc89i63e
    Molecular Formula
    C24H24F3N5O5S3
    Molecular Weight
    615.7  g/mol
    InChI Key
    YKGMKSIHIVVYKY-UHFFFAOYSA-N
    FDA UNII
    B6DC89I63E
    Dabrafenib Mesylate
    Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
    1 2D Structure

    Dabrafenib Mesylate

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid
    2.1.2 InChI
    InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)
    2.1.3 InChI Key
    YKGMKSIHIVVYKY-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    B6DC89I63E
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1195768-06-9

    2. Dabrafenib (mesylate)

    3. Gsk 2118436b

    4. Dabrafenib Mesilate

    5. Dabrafenib Mesylate [usan]

    6. Unii-b6dc89i63e

    7. Gsk-2118436 Mesylate

    8. Gsk-2118436b

    9. Methane Sulfonate Salt

    10. Gsk2118436b

    11. Gsk2118436 Mesylate

    12. B6dc89i63e

    13. Chebi:75048

    14. Gsk-2118436b Mesylate

    15. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide Methanesulfonate

    16. Gsk2118436b, Methane Sulfonate Salt

    17. Gsk-2118436 Methanesulfonate Salt

    18. Gsk-2118436b Methanesulfonate Salt

    19. Gsk2118436 Mesylate;gsk 2118436b

    20. Dabrafenib Mesilate (jan)

    21. Dabrafenib Mesylate (gsk-2118436)

    22. Dabrafenib Mesylate (usan)

    23. Dabrafenib Mesilate [jan]

    24. Taflinar

    25. N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic Acid

    26. Dabrafenib Methanesulfonate

    27. Tafinlar (tn)

    28. Gsk2118436 Methane Sulfonate Salt

    29. Dabrafenib Monomesylate

    30. Gsk 2118436 Mesylate

    31. Schembl1127269

    32. Chembl2105729

    33. Dabrafenib Mesylate [mi]

    34. Dtxsid70152500

    35. Amy30045

    36. Bcp04738

    37. Ex-a1559

    38. Dabrafenib Mesilate [who-dd]

    39. Hy-14660a

    40. Mfcd20922872

    41. S5069

    42. Akos025396661

    43. Ccg-270246

    44. Cs-1641

    45. Dabrafenib Mesylate [orange Book]

    46. Ac-31302

    47. As-17010

    48. Ft-0696677

    49. D10104

    50. A903491

    51. Sr-01000941590

    52. Sr-01000941590-1

    53. Q27145089

    54. Gsk2118436 Ms Salt, Dabrafenib Ms Salt, Gsk2118436a Ms Salt

    55. Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)- 2-fluorophenyl)-2,6-difluoro-, Methanesulfonate (1:1)

    56. Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, Methanesulfonate (1:1)

    57. Dabrafenib Mesylaten-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide, Methanesulfonic Acid; Dabrafenib Mesylate

    58. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl)-2,6- Difluorobenzenesulfonamide Monomethanesulfonate

    59. N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

    60. N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

    2.3.2 Other Synonyms

    1. 1195765-45-7

    2. Dabrafenib

    2.4 Create Date
    2009-12-22
    3 Chemical and Physical Properties
    Molecular Weight 615.7 g/mol
    Molecular Formula C24H24F3N5O5S3
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count14
    Rotatable Bond Count6
    Exact Mass615.08916689 g/mol
    Monoisotopic Mass615.08916689 g/mol
    Topological Polar Surface Area210 Ų
    Heavy Atom Count40
    Formal Charge0
    Complexity910
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    * Melanoma:

    Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4. 4 and 5. 1).

    * Adjuvant treatment of melanoma:

    Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

    * Non-small cell lung cancer (NSCLC):

    Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

    Treatment of melanoma, Treatment of solid malignant tumours (excluding melanoma)

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    L01EC02

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1701714600,"product":"PHARMA INGREDIENTS - DABRAFENIB MESYLATE(FORM-I) IN-HOUSE","address":"30, AROHI VILLA, S.P. RING ROAD, BOPAL,","city":"AHMEDABAD","supplier":"GREENCROSS EXPORT PRIVATE ","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"TO THE ORDER -- +-","customerCountry":"RUSSIA","quantity":"0.38","actualQuantity":"0.38","unit":"KGS","unitRateFc":"90000","totalValueFC":"33576.3","currency":"USD","unitRateINR":7355263.1578947371,"date":"05-Dec-2023","totalValueINR":"2795000","totalValueInUsd":"33576.3","indian_port":"Ahmedabad Air","hs_no":"29335920","bill_no":"5811376","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"30, AROHI VILLA, S.P. RING ROAD, BOPAL,, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702578600,"product":"DABRAFENIB MESYLATE (FORM-I)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"AMEDART LLC","customerCountry":"RUSSIA","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"250000","totalValueFC":"4516.9","currency":"USD","unitRateINR":18800000,"date":"15-Dec-2023","totalValueINR":"376000","totalValueInUsd":"4516.9","indian_port":"Hyderabad Air","hs_no":"29335920","bill_no":"6074440","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
    05-Dec-2023
    15-Dec-2023
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - CAPSULE;ORAL - EQ 50MG BASE

    USFDA APPLICATION NUMBER - 202806

    read-more

    DOSAGE - CAPSULE;ORAL - EQ 75MG BASE

    USFDA APPLICATION NUMBER - 202806

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search